The Lancet· Myriam Chalabi, Lauren D W van den Dungen, Peter G M de Gooyer, Sara Balduzzi, Arend G J Aalbers, Emile D Kerver, Cecile Grootscholten, Simone Dokter, Johanne G Bloemen, Eddy R Hendriks, Tjeerd S Aukema, Steven J Oosterling, Wieke H M Verbeek, Emile E Voest, Niels F M Kok, Marnix H Geukes Foppen, Regina G Beets-Tan, Antony Tin, Adham Jurdi, Ton N Schumacher, Monique E van Leerdam, José G van den Berg, John B A G Haanen·· 4 hours agoPickScore73
[Articles] Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
In brief
The Dutch single-arm, multicentre, phase 2 NICHE-2 trial showed that patients with locally advanced dMMR colon cancer who received ipilimumab and nivolumab before surgery had 3-year disease-free survival and 5-year overall survival of 100%. The authors consider that this neoadjuvant combination may become a standard treatment option for locally advanced dMMR colon cancer.
Why it matters
This single-arm multicentre phase 2 study reports 100% 3-year DFS and 5-year OS, offering long-term follow-up for efficacy assessment without a concurrent control.
Source: The Lancet · thelancet.com